CASALONGA

Follow

Patents in France

France, Global - January 22 2019 A structured guide to patents law and practice in France

Article 3 (a) of Regulation (EC) 4692009 : What is the meaning of “protected by a basic patent”

European Union, France - May 29 2018 By judgment of May 25th, 2018, the Paris Court of First Instance nullified the SPC on the combination of "tenofovir disoproxil and its salts, hydrates

Second medical indication and SPC - Referral to the CJEU for a preliminary ruling on the interpretation of Article 3d) of Regulation (EC) No 4692009 in the light of the NEURIM judgment (CJEU C-13011), by the Court of Appeal of Paris 9 October 2018

France - October 25 2018 The use of a submicron oil-in-water ophthalmic emulsion comprising an immunosuppressive agent selected from the group consisting of ciclosporin

Anti-counterfeiting 2009 - A Global Guide: France

France - April 30 2009 IP regulation is codified within the French IP Code

Dismissal of the preliminary injunction request based on SPC covering the combination of ezetimibe and simvastatin

France - July 6 2018 Interpretation of articles 3 (c) and 3 (d) of Regulation (EC) No. 4692009 The Paris Court of Appeal uphold the Interim Order of the Paris Court of

Patents in France

France, Global - January 22 2019 A structured guide to patents law and practice in France

Patentability in France

France, Global - January 22 2019 An overview of patentability in France

Patent enforcement through the courts in France

France, Global - January 22 2019 A structured guide to enforcing patents through the courts in France

Second medical indication and SPC - Referral to the CJEU for a preliminary ruling on the interpretation of Article 3d) of Regulation (EC) No 4692009 in the light of the NEURIM judgment (CJEU C-13011), by the Court of Appeal of Paris 9 October 2018

France - October 25 2018 The use of a submicron oil-in-water ophthalmic emulsion comprising an immunosuppressive agent selected from the group consisting of ciclosporin

Judgment of 25 July 2018 of the Grand Chamber of the Court of Justice of the Europen Union - The Chamber rules on the interpretation of article 3a) of Regulation (EC) No. 4692009

European Union - August 3 2018 The company GILEAD markets under the name TRUVADA, an antiretroviral drug indicated for the treatment of HIV patients